News - Appointments

Joshua Brumm, chief executive of Dyne Therapeutics Inc, has been named chair of UK-based Amphista Therapeutics Ltd, which has technology for targeted protein degradation.

Mark Capone, a former chief executive of Myriad Genetics Inc, has joined the board of UK-based Owlstone Medical Ltd to help it advance its breath-based diagnostics for cancer and respiratory disease.

AM-Pharma BV of the Netherlands has appointed Lars Boesgaard as chief financial officer to be based in the US, in preparation for the potential commercialisation of its candidate product for sepsis-associated acute kidney injury.

Finland-based Rappta Therapeutics Oy has appointed Sunjeet Sawhney as chief executive to manage development of its cancer drugs that reactivate PP2A, an enzyme that regulates protein de-phosphorylation. He was most recently global head of oncology at Ipsen SA.

Ruth McKernan has been appointed chair of Cumulus Neuroscience Ltd of Belfast, UK which has a platform for generating biomarkers for trials of drugs for central nervous system disorders.

Oliver Schon, an expert in antibody-based therapeutic development, has been named head of product development and chemistry, manufacturing and controls (CMC), at BiVictriX Therapeutics Plc, a UK developer of cancer therapies.

Erik Skullerud, a Norwegian national and resident of Switzerland, has been named chief executive of Nordic Nanovector ASA to help advance the company’s radionuclide conjugate therapies for cancer.

Donald Nicholson, a former executive at Merck & Co Inc, has joined Muna Therapeutics ApS as an independent chair of the company’s board of directors. Muna is developing therapies for neurodegenerative disorders.

Anna Hale, formerly of GlaxoSmithKline Consumer Healthcare, is to join Karo Pharma AB as chief marketing officer. Based in Sweden, Karo sells over-the-counter products and prescription medicines. Before GSK, Ms Hale spent eight years at the UK consumer goods company Reckitt.

Jeffrey Abbey, a pharma executive and lawyer, has joined ImmunOs Therapeutics AG of Switzerland as chief operating officer as the company prepares for clinical trials of its biologics for cancer and autoimmune diseases.